Primary cutaneous aggressive epidermotropic cytotoxic CD8⁺ T-cell lymphoma: long-term remission after brentuximab vedotin

Int J Dermatol. 2017 Dec;56(12):1448-1450. doi: 10.1111/ijd.13792. Epub 2017 Oct 19.

Authors

Benoit M Cyrenne¹, Antonio Subtil², Michael Girardi¹, Francine Foss³

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
² Department of Dermatology and Pathology, Yale School of Medicine, New Haven, CT, USA.
³ Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT, USA.

PMID: 29047111
DOI: 10.1111/ijd.13792

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Brentuximab Vedotin
CD8-Positive T-Lymphocytes
Female
Humans
Immunoconjugates / therapeutic use*
Lymphoma, T-Cell, Cutaneous / drug therapy*
Middle Aged
Remission Induction
Retreatment
Skin Neoplasms / drug therapy*
Time Factors

Substances

Antineoplastic Agents, Immunological
Immunoconjugates
Brentuximab Vedotin